Skip to main content
. 2020 Jun;9(3):1252–1261. doi: 10.21037/tau-19-755

Table 2. Clinical and MRI data evaluated of peripheral lesions.

Clinical and MRI data Non-clinically significant cancer (n=44) Clinically significant cancer (n=10) P values
Age (years), mean [SD] 67 [9] 76 [8] 0.013a
tPSA (ng/mL), median (IQR) 8.39 (5.52–13.89) 14.28 (7.89–20.27) 0.111a
fPSA (ng/mL), median (IQR) 0.91 (0.53–1.92) 1.00 (0.78–2.42) 0.703a
f/tPSA, median (IQR) 0.12 (0.93–1.88) 0.09 (0.05–0.14) 0.182a
PSAD (ng/mL2), median (IQR) 0.19 (0.11–0.36) 0.31 (0.19–1.06) 0.012a
PV (mL), median (IQR) 39.01 (29.78–69.45) 36.66 (24.94–46.58) 0.122a
Lesion diameter (mm), mean (SD) 17.57 (3.61) 19.43 (2.94) 0.134a
Lesion location, n (%) 0.817b
   Base 9 (20.5) 3 (30.0)
   Middle 14 (31.8) 3 (30.0)
   Apex 21 (47.1) 4 (40.0)

a, univariate cox regression analysis; b, chi-square test. MRI, magnetic resonance imaging; SD, standard deviation; IQR, interquartile range; tPSA, total prostate-specific antigen; fPSA, free PSA; f/tPSA, ratio of free-to-total PSA; PSAD, PSA density; PV, prostate volume.